Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...
Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...
Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
Eli Lilly also announced an $800 million facility expansion in Kinsale, Ireland. That site started to manufacture drugs ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other counter cyclical and defensive stocks to invest in. Volatility in the U.S. equity ...
It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback